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Abstract
Background: The revised version of the Fibromyalgia Impact Questionnaire (FIQR) is one of the most widely used
specific questionnaires in FM studies. However, this questionnaire does not allow calculation of QALYs as it is not a
preference-based measure. The aim of this study was to develop mapping algorithm which enable FIQR scores to
be transformed into utility scores that can be used in the cost utility analyses.
Methods: A cross-sectional survey was conducted. One hundred and 92 Spanish women with Fibromyalgia were
asked to complete four general quality of life questionnaires, i.e. EQ-5D-5 L, 15D, AQoL-8D and SF-12, and one specific
disease instrument, the FIQR. A direct mapping approach was adopted to derive mapping algorithms between the
FIQR and each of the four multi-attribute utility (MAU) instruments. Health state utility was treated as the dependent
variable in the regression analysis, whilst the FIQR score and age were predictors.
Results: The mean utility scores ranged from 0.47 (AQoL-8D) to 0.69 (15D). All correlations between the FIQR total
score and MAU instruments utility scores were highly significant (p < 0.0001) with magnitudes larger than 0.5.
Although very slight differences in the mean absolute error were found between ordinary least squares (OLS)
estimator and generalized linear model (GLM), models based on GLM were better for EQ-5D-5 L, AQoL-8D and 15D.
Conclusion: Mapping algorithms developed in this study enable the estimation of utility values from scores in a
fibromyalgia specific questionnaire.
Keywords: EQ-5D-5 L, 15D, AQoL-8D, SF-6D
Background
Fibromyalgia (FM) is a chronic disease characterized by
widespread pain and several associated symptoms, such
as non-restorative sleep, fatigue, poor physical condi-
tioning, impaired cognition, stiffness, depression, and
balance impairment [25, 32]. These symptoms often lead
a reduction in health-related quality of life (HRQoL) [9].
Although the causes of FM are still unknown, the up to
date most accepted hypothesis is the sensitization of the
central nervous system [14], which proposes that the
cause of the high level of pain is the amplification of the
sensory inputs by the central nervous system.
In Spain, approximately 4.2% of the women suffer from
this disorder, whereas only 0.2% of the men are affected
[19]. FM imposes significant economic burden as patients
often have a high prevalence of work loss [31, 34].
Approximately 40–44% of patients are employed either
full- or part-time, and the annual days missed from work
are 23.2–32.5 days per year [18].
Most FM patients (83–93%) are taking at least one
prescription medication, and 56–73% are taking two or
more [18]. However, less than 50% of patients report be-
ing extremely or somewhat satisfied. Economic
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evaluations of health services are commonly used to
help making decisions since resources for health care are
not unlimited. These economic evaluations commonly
use quality-adjusted life years (QALYs) as the unit of
analysis. The estimation of the cost of obtaining an add-
itional QALY is based on the cost-utility analysis (CUA).
QALY is a single measure that comprises mortality and
morbidity combining the effect on survival in years and
HRQoL experienced in those years [28]. The health state
utility score, which lies on a 0–1 death-full health QALY
scale, is used to weight life years to reflect HRQoL. The
priority is usually given to the service which results in
the highest increase of QALYs for a specified cost.
The results from multi-attribute utility (MAU) question-
naires can be scored using a predetermined algorithm or
weights for estimating the health utilities, which are
required to calculate QALYs [6]. Clinical studies with FM
patients frequently include disease specific questionnaires
which have been designed to assess relevant aspects of
health that are relevant for the disease, i.e. stiffness, sleep
quality, fatigue, etc. The most widely used specific ques-
tionnaires in FM studies are the fibromyalgia impact ques-
tionnaire (FIQ) [3] and its revised version (FIQR) [5].
However, these two questionnaires do not allow calcula-
tion of QALYs as they are not preference-based measures.
The development of mapping algorithms that enable
results from disease specific questionnaires to be used in
CUA is a common strategy to address the mentioned limi-
tation [8]. This procedure has been performed in other
diseases with other disease specific questionnaires, such as
rheumatoid arthritis [2], idiopathic overactive bladder
[12], diabetes [11], or cancer [17]. However, to our know-
ledge, there is no study on the development of a mapping
algorithm for a FM-specific questionnaire.
The objective of the current study was to develop
mapping algorithms which enable the Spanish version of
FIQR scores to be transformed into utility scores that
can be used in the CUA.
Methods
Design
A cross-sectional survey with a convenience sample was
conducted between October 2014 and October 2015. Re-
cruitment was performed at four local Spanish FM associ-
ations. The sample consisted of 192 women with FM,
aged between 23 and 83 years. The inclusion criteria was:
a) being a woman diagnosed with FM by a rheumatologist
accordingly with the criteria of the American College of
Rheumatology [33], b) being able to communicate effect-
ively with the study staff, and (c) reading and signing the
written informed consent. Data were collected through
face-to-face interviews conducted by one trained and ex-
perienced researcher. Participants answered the interviews
in a quiet room placed at the association’s facilities. These
data were used to develop mapping algorithms between
each of the four MAU instruments (EQ-5D-5 L, AQoL-
8D, 15D and SF-6D) and the FIQR.
Instruments
Four MAU instruments (Spanish version) were included
in the present study. The first one is the five-level ver-
sion of the world’s most widely used MAU instrument
the EQ-5D. The EQ-5D-5 L [16] comprises 5 dimen-
sions and with 5 possible levels for each dimension,
defining a total of 3125 health states. The EQ-5D-5 L
utility index for Spain is the result of a “crosswalk” from
the EQ-5D-3 L [29]. The algorithm is available at EuroQol
Group’s website (http://http://www.euroqol.org/). The EQ-
5D is the most sensitive MAU instrument for measuring
pain [22]. The 15D questionnaire [27] includes 15 items
and 5 possible levels for each one, defining 3.05 * 1010
states. The AQoL-8D [23] includes 8 dimensions defining
2.37 *1023 states and it is the most sensitive instrument for
measuring the psychosocial component [22]. The fourth
MAU instrument used in the current study was the SF-6D
[7], which was derived from SF-12 questionnaire and
defines 18,000 health states.
The FIQR was selected as the disease specific instrument
for mapping analysis. It evaluates the impact of FM ad-
dressing the limitations encountered in the FIQ while
retaining the essential properties of the original instrument
[5]. In this regard, the original FIQ was intended for women
living in developed countries and assumed the possession
of a car, a vacuum cleaner, and a washing machine. Add-
itionally, some symptoms were included in FIQR, such as
cognitive problems, tenderness, balance, and environmental
sensitivity. In general terms, FIQR has replaced the original
FIQ for routine use in FM related studies and clinical use.
The total score of FIQR ranges from 0 to 100 and is calcu-
lated as the sum of the three domains: function domain
(upper limit 30), overall impact domain (upper limit 20),
and symptom domain (upper limit 50). The function
domain includes nine items, the overall impact domain two
items and the symptom domain includes 10 items. The
validation of the Spanish version of FIQR was performed
by Salgueiro et al. [24] in 2013.
Statistical analysis
A direct mapping approach was adopted to derive map-
ping algorithms between the FIQR and each of the four
MAU instruments. In essential, health state utility was
treated as the dependent variable in the regression ana-
lysis, whilst the FIQR score and potential demographic
characteristics were predictors. The regression based dir-
ect mapping is the most commonly adopted approach in
the mapping literature [20]. Two models specifications
were considered in this study. In the first model, the
total FIQR score was the key independent variable, whilst
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in the second model, three domains of FIQR were key
independent variables. Since participants in the current
study were only women, only age was included as demo-
graphic variable. The squared terms of the dimensions
and total score of FIQR were also considered in models
as a way to capture non-linear effects. Independent var-
iables were included in the model when p-value was
lower than 0.05.
Two statistical approaches were used to calculate the
two models. The first was the ordinary least squares
(OLS) estimator, which is the most widely used technique
[8, 20]. The second technique was the generalized linear
model (GLM), which allows estimations for non-normal
distributions [15]. The Gamma family with log link was
chosen for the models based on the goodness of fit results.
Some pre-transformations were made before variables
were entered in the model. The FIQR total/domain
scores were firstly transformed onto the 0–1 scale by
dividing the raw scores by the maximum total/domain
scores, thus FIQR total score was divided by 100, func-
tion domain was divided by 30, overall impact domain
by 20 and symptom domain was divided by 50. Regard-
ing the EQ-5D-5 L, the original score includes negative
values as it ranges from −0.654 to 1. The scale was
transformed into strictly positive by adding 0.66, i.e. the
whole distribution of the EQ-5D-5 L utility was moved
to the right, whilst the shape of distribution remains
identical. Thus the new scale ranged from 0 to 1.66. This
adjustment allows the gamma family with log link to be
used in the GLM estimation.
Goodness-of-fit was examined using the mean absolute
error (MAE) and the root mean square error (RMSE). The
lower MAE/RMSE values represents better mapping per-
formance. To enable comparisons with other studies, the
R-squared were calculated for OLS models.
An internal validation analysis was performed. The
whole sample was randomly divided into five groups. In
each group 80% of the sample was used to calculate the
mapping algorithm and the remaining 20% was used to
predict the MAU utility with the above mapping algo-
rithm. These procedure was repeated for each of the five
groups, so all groups were used as both predictor and
predicted sample. MAE and RMSE were calculated in
this validation analysis. This approach has been widely
used in internal validation and commonly referred to as
a cross-validation approach in the literature [12, 13].
All analyses were performed using Microsoft Excel
2007 software program and SPSS version 21 (IBM).
Results
Sample characteristics
A total of 192 women with FM aged 53.77 (10.02) years
(ranged between 23 and 83 years) participated in the
study. More than a half of the women (54.2%) were
diagnosed between 5 and 15 years ago, and most of
them (68.8%) are suffering pain and other FM symptoms
since 5–25 years (see Table 1).
Depending on the generic MAU instruments studied,
the mean utility scores ranged from 0.47 (AQoL-8D) to
0.69 (15D). Regarding the FM-specific measure, partici-
pants had a mean (SD) FIQR score of 56.77 (20.77).
According to the cut-off point between moderate and
severe FM (i.e. FIQR = 59) [4, 5], on average participants
had moderate to severe FM.
Associations between instruments
Pearson correlation (R) coefficients between MAU instru-
ments and FIQR domains/total scores are presented in
Table 2. As can be seen, all correlations are highly signifi-
cant (all p < 0.0001) with magnitudes larger than 0.5). The
correlations are stronger between MAU instruments and
the FIQR total score than the FIQR domain score. Among
three domains, the symptom domain showed stronger
Table 1 Descriptive statistics of women with fibromyalgia (FM)
Patient characteristics n = 192a
Mean age, years (SD) 53.77 (10.02)
Education status for participants (%)
Non-university studies 161 (83.9)
University studies 31 (16.1)
Ocuppational status (%)
Employee 77 (40.1)
Non employee 115 (59.9)
Mean years since clinical diagnosis of FM, n (%)
< 5 years 21 (10.9)
5–15 years 104 (54.2)
15–25 years 37 (19.3)
25–55 years 14 (7.3)
Mean years since onset of symptoms, n (%)
< 5 years 6 (3.1)
5–15 years 67 (34.9)
15–25 years 65 (33.9)
25–55 years 36 (18.8)
EQ-5D-5 L Utility, mean (SD) 0.49 (0.26)
AQoL-8D Utility, mean (SD) 0.47 (0.17)
15D Utility, mean (SD) 0.69 (0.12)
SF-6D Utility, mean (SD) 0.56 (0.10)
FIQR function domain, mean (SD) 15,76 (7,10)
FIQR overall impact domain, mean (SD) 9,87 (6,07)
FIQR symptom domain, mean (SD) 31,13 (10,14)
FIQR Score, mean (SD) 56.77 (20.77)
an = 191 for EQ-5D-5 L, n = 177 for AQoL-8D, n = 192 for 15D, n = 141 for
SF-6D. FIQR function domain (upper limit 30); FIQR overall impact domain (upper
limit 20); FIQR symptom domain (upper limit 50); FIQR Score (range 0–100)
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association than the other two dimensions for EQ-5D-5 L,
AQoL-8D, and 15D, whereas for SF-6D, the overall impact
domain showed the highest R value. Overall speaking,
among four MAU instruments, the correlation between
EQ-5D-5 L and FIQR was the strongest.
Mapping results
Table 3 presents the goodness-of-fit for the four ana-
lyzed MAU instruments using full data. Two panels can
be identified: Panel A shows the model with FIQR,
squared FIQR and age, while Panel B includes the model
with the three dimensions of FIQR, the three squared-
dimensions of FIQR and age.
The predicted mean utilities using OLS or GLM were
always identical to the observed means. Regarding the pre-
dicted utility range all models tended to under predict the
highest utility and over predict the lowest utility. Highest
discrepancies between the predicted minimum and the
observed minimum were found for EQ-5D, while the low-
est differences were observed in SF-6D. OLS always pre-
dicted a minimum closer to the observed one compared
to GLM. Both OLS and GLM tended to under predict the
maximum scores, with highest discrepancies in SF-6D and
good accuracy for 15D. The performance of GLM predict-
ing maximum scores were much better than OLS, espe-
cially in the AQoL-8D model.
MAE and RMSE were calculated as key goodness-of-
fit measures. The MAE was lowest for SF-6D (0.063)
and highest for EQ-5D-5 L (0.137). The MAE for
AQoL-8D and 15D was 0.097 and 0.069 respectively.
Although very slight differences in the MAE were
found between OLS and GLM, models based on GLM
were better for EQ-5D-5 L, AQoL-8D and 15D. MAE
values were identical for SF-6D. Similar results were
observed for RMSE.
The R-squared statistics ranged from 0.465 for AQoL-8D
in the Panel A to 0.579 for EQ-5D-5 L in the Panel A.
Judging on the R-squared, the mapping performance of the
AQoL-8D model was better in Panel B, i.e. using FIQR
domain scores instead of the total score as key predic-
tors. This conclusion is also applicable to the SF-6D.
On the other hand, EQ-5D-5 L and 15D showed higher
R-squared statistic values in the Panel A using total
score of the FIQR.
Table 4 shows the goodness-of-fit from the validation
analysis. The MAE and RMSE were similar to those
reported in Table 3. Highest discrepancies were observed
in the Panel B of SF-6D, where MAE was enhanced from
0.063 in Table 3 to 0.066 and 0.067 in Table 4 for OLS
and GLM respectively. RMSE was also increased in the
validation analysis from 0.079 to 0.084. The best model
for predicting utilities from the FIQR differs depending
on the MAU instruments. The best model for AQoL-8D
is the GLM as the MAE and RMSE were lower com-
pared to OLS. Performance with Panel A or Panel B was
very close: MAE was slightly lower in Panel A and
RMSE was slightly lower in Panel B. Range was also very
close. The validation analysis showed slightly lower
MAE for Panel A (0.096 vs 0.097) and the same RMSE,
but the predicted range was much better in Panel B, as
the maximum was 0.901 while it was 0.837 in Panel A.
Therefore, both models, using FIQR score and dimen-
sions can be accepted. The best model for 15D is the
GLM using FIQR dimensions, as the MAE and RMSE
were slightly lower. As happened with AQoL-8D, all
models seemed to be valid and differences between them
were very small. The performance of the model for
EQ-5D-5 L and SF-6D were also similar for both types of
statistical approach and panels. No clear differences were
observed in terms of MAE and RMSE, and the range was
slightly better for GLM in the Panel B. Validation analysis
confirmed this tendency.
Table 5 reports the detailed significant regression coeffi-
cients for each mapping algorithm. Age was only signifi-
cant in predicting 15D utility. Results from Table 5 can be
utilized to predict health state utility in case only FIQR
score is available. For example, the optimal mapping algo-
rithm from FIQR domain scores to the SF-6D utility is
derived based on the OLS estimator, and can be written as:
SF-6D utility = 0.786–0.137*FIQR_D1–0.089*FIQR_D2–
0.149*FIQR_D3where FIQR_Di (i = 1, 2, 3) are pre-
adjusted domain scores; FIQR_D1 is the function domain,
FIQR_D2 is the overall impact domain, and FIQR_D3 is
the symptom domain.
Discussion
The funding of drugs and medical services in health
schemes is increasingly contingent upon the successful
outcome of an economic evaluation. When HRQoL is
Table 2 Pearson correlations between the generic multi-attribute utility instruments and the FIQR scores
EQ-5D-5 L utility n = 191 AQoL-8D utility n = 177 15D utility n = 192 SF-6D utility n = 141
FIQR function domain –.668** −.523** −.592** −.599**
FIQR overall impact domain −.653** −.598** −.593** −.605**
FIQR symptom domain −.686** −.668** −.673** −.595**
FIQR Score −.749** −.682** −.704** −.684**
**All correlations were statistically significant, P < 0.0001
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an important outcome regulatory authorities (e.g. the
National Institute for Health and Care Excellence in the
United Kingdom) generally recommend or require the
use of CUA, which implies the need to use health state
utility as the outcome measure. This study investigated
four generic MAU and one disease-specific instruments
on patients with FM. In addition, based on this unique
dataset, a set of mapping algorithms were reported so
that health state utilities can be predicted when only
FIQR is administrated. This study is the first enabling
the estimation of utility values from scores in a FM spe-
cific questionnaire.
The severity of symptoms of women with FM who
participated in the current study was very similar to the
previous study where FIQR was validated [5]. In that
study, mean score ± SD was 56.6 ± 20.0, while results in
Table 1 of this manuscript showed a mean score ± SD of
56.77 ± 20.77. Therefore, the patient sample used to
derive/validate mapping algorithm covers the most com-
monly observed FM severity in clinical practice.
There were relevant differences between utility scores
of the four analyzed MAU instruments. Among them,
the EQ-5D-5 L was found to have the strongest correl-
ation (−0.749) with FM-specific measure. This is prob-
ably because the EQ-5D-5 L primarily reflect pain and
physical function (Richardson et al. [22]). Since pain is
the main symptom of FM and the impact of the disease
on physical health may be even higher than the impact
on psychological health [26], it seems reasonable that
this questionnaire presented higher correlation coeffi-
cient (−0.749) when it was correlated with FIQR. On the
other hand, the mean utility score of AQoL-8D was the
lowest among four MAU instruments. This contrasts
with the results for healthy population, when lowest
Table 3 Goodness-of-fit results for mapping FIQR scores onto multi attribute utilities
PANEL A
Instruments N Method Mean Utility Min Utility Max Utility MAE RMSE R-squared
AQoL-8D 177 Observed 0.465 0.155 0.945 - -
OLS 0.465 0.213 0.778 0.097 0.124 0.465
Gamma GLM 0.465 0.267 0.866 0.095 0.123
15D 192 Observed 0.688 0.391 1.000 - -
OLS 0.688 0.487 0.931 0.069 0.087 0.507
Gamma GLM 0.688 0.510 0.967 0.069 0.087
EQ-5D-5 L 191 Observed 0.490 −0.480 1.000 - -
OLS 0.490 −0.079 0.819 0.138 0.174 0.579
Gamma GLM 0.490 0.011 0.870 0.137 0.174
SF-6D 141 Observed 0.561 0.345 1.000 - -
OLS 0.561 0.411 0.737 0.063 0.079 0.468
Gamma GLM 0.561 0.428 0.756 0.063 0.079
PANEL B
Instruments N Method Mean Utility Min Utility Max Utility MAE RMSE R-squared
AQoL-8D 177 Observed 0.465 0.155 0.945 - -
OLS 0.465 0.228 0.787 0.097 0.123 0.480
Gamma GLM 0.465 0.275 0.876 0.096 0.122
15D 192 Observed 0.688 0.391 1.000 - -
OLS 0.688 0.507 0.950 0.071 0.088 0.492
Gamma GLM 0.688 0.511 0.979 0.068 0.086
EQ-5D-5 L 191 Observed 0.490 −0.480 1.000 - -
OLS 0.490 −0.081 0.836 0.138 0.175 0.573
Gamma GLM 0.490 0.010 0.890 0.137 0.176
SF-6D 141 Observed 0.561 0.345 1.000 - -
OLS 0.561 0.410 0.737 0.063 0.079 0.472
Gamma GLM 0.561 0.427 0.756 0.063 0.079
Panel A: FIQR, Squared-FIQR, Age
Panel B: FIQR function domain; FIQR overall impact domain; FIQR symptom domain; Squared FIQR function domain; Squared FIQR overall impact domain; Squared
FIQR symptom domain; Age. Gamma GLM: Generalized linear model Gamma log-link
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scores are often observed for SF-6D. That could indi-
cate that social component has large impact in the
HRQoL of women with FM as it was reported in previ-
ous studies [1, 35].
R-squared coefficient is often about 0.5 when mapping
is performed from a generic onto generic preference-
based questionnaires. However, this value is commonly
reduced to 0.2–0.4 when mapping is performed from dis-
ease specific to generic questionnaires [8]. The R-squared
in the current study ranged from 0.465 for AQoL in the
Panel A to 0.579 for EQ-5D-5 L in the Panel B. This high
scores indicate strong relation between FIQR and HRQoL,
and highlight the relevance of pain and physical function
in the utility score of EQ-5D-5 L.
The study has several limitations. Firstly, the range of
the predicted utilities was narrower than the observed
utilities. This is a commonly reported limitation in map-
ping literature [11, 12, 30]. This range was particularly
narrow in EQ-5D-5 L and SF-6D. As can be seen in the
supplemental file, the distribution of these question-
naires in the sample of the current study may have
increased this problem. Specifically, one women scored
−0.480 in EQ-5D-5 L, while the second lowest score in
this questionnaire was −0.133. Therefore, if this anomal-
ous value was removed, the observed minimum would
be −0.133, which is similar to the predicted minimum
(−0.08 using OLS and 0.01 using GLM). Similarly, the
SF-6D utility score of one woman was 1, while the
Table 4 Goodness-of-fit results from validation analysis
PANEL A
Instruments N Method Mean Utility Min Utility Max Utility MAE RMSE
AQoL-8D 177 Observed 0.465 0.155 0.945 - -
OLS 0.465 0.214 0.751 0.099 0.126
Gamma GLM 0.465 0.269 0.837 0.096 0.124
15D 192 Observed 0.688 0.391 1.000 - -
OLS 0.688 0.484 0.927 0.070 0.087
Gamma GLM 0.688 0.511 0.965 0.069 0.087
EQ-5D-5 L 191 Observed 0.490 −0.480 1.000 - -
OLS 0.490 −0.076 0.814 0.138 0.174
Gamma GLM 0.489 0.016 0.871 0.137 0.175
SF-6D 141 Observed 0.561 0.345 1.000 - -
OLS 0.560 0.415 0.739 0.064 0.081
Gamma GLM 0.560 0.431 0.756 0.064 0.081
PANEL B
Instruments N Method Mean Utility Min Utility Max Utility MAE RMSE
AQoL-8D 177 Observed 0.465 0.155 0.945 - -
OLS 0.465 0.218 0.808 0.098 0.124
Gamma GLM 0.465 0.271 0.901 0.097 0.124
15D 192 Observed 0.688 0.391 1.000 - -
OLS 0.689 0.498 0.942 0.072 0.089
Gamma GLM 0.689 0.521 0.985 0.071 0.089
EQ-5D-5 L 191 Observed 0.490 −0.480 1.000 - -
OLS 0.491 −0.085 0.843 0.138 0.174
Gamma GLM 0.490 0.014 0.891 0.137 0.175
SF-6D 141 Observed 0.561 0.345 1.000 - -
OLS 0.559 0.411 0.743 0.066 0.084
Gamma GLM 0.559 0.428 0.761 0.067 0.084
Validation analysis dividing the sample into 5 groups (80% as predictor and 20% as predicted)
Panel A: FIQR, Squared-FIQR, Age
Panel B: FIQR function domain; FIQR overall impact domain; FIQR symptom domain; Squared FIQR function domain; Squared FIQR overall impact domain; Squared
FIQR symptom domain; Age
Gamma GLM: Generalized linear model Gamma log-link
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second best utility score in this instrument was 0.86.
Again, the narrow range problem is largely caused by an
extreme value, as the predicted maximum was 0.756
(GLM model). Therefore, it should be noticed that the
model performance is reduced for extreme values.
Although there are previous mapping studies with smaller
sample size [12, 20], this may represent the second limita-
tion. Another limitation regarding the sample is the
absence of males. This is important because the mapping
algorithms from the current study should only be applied
to women and not men. Given the scarce of men diag-
nosed with FM in Spain and the large sex differences
among FM patients [10, 21], studies are commonly fo-
cused in one of the two genders. However, further studies
are encouraged to develop a mapping algorithm for men
suffering from FM. The fourth limitation is the validation
of the model using internal data. Although the absence of
an external validation is not uncommon, external
Table 5 Mapping equations from FIQR score to multi-attribute utility instruments
AQoL-8D 15D EQ-5D-5 L SF-6D
Coeff. SE Coeff. SE Coeff. SE Coeff. SE
PANEL A
OLS
Constant .778 .027*** .997 .039*** 1.479 .024*** .794 .022***
FIQR/100 −.564 .046*** −.420 .030*** −.383 .035***
Age −.001 .001*
Squared-FIQR −.898 .056***
GLM
Constant −.144 .060* .068 .058 .425 .025*** −.179 .039***
FIQR/100 -1.175 .101*** −.600 .046*** −.670 .061***
Age −.002 .001*
Squared-FIQR −.824 .058***
PANEL B
OLS
Constant .787 .031*** .950 .021*** 1.496 .027*** .786 .025***
Age
FIQR_D1 −.138 .036*** −.137 .043**
FIQR_D2 −.144 .043** −.089 .034**
FIQR_D3 −.415 .065*** −.305 .042*** −.149 .049**
Squared FIQR_D1 −.335 .081***
Squared FIQR_D2 −.167 .064**
Squared FIQR_D3 −.415 .084***
GLM
Constant −.132 .068* .078 .059 0.438 .028*** −.192 .044***
Age −.002 .001*
FIQR_D1 −.156 .058** −.241 .075**
FIQR_D2 −.318 .096** −.096 .048* −.153 .059**
FIQR_D3 −.840 .147*** −.359 .070*** −.264 .085**
Squared FIQR_D1 −.304 .081***
Squared FIQ_D2 −.167 .065**
Squared FIQR_D3 −.368 .086***
Coeff. and SE: Beta and Standard error of significant variables (*p < 0.05, **p < 0.01; ***p < 0.001) in the equations
Panel A: FIQR, Squared-FIQR, Age
Panel B: FIQR function domain (FIQR_D1); FIQR overall impact domain (FIQR_D2); FIQR symptom domain (FIQR_D2); Squared FIQR function domain; Squared FIQR
overall impact domain; Squared FIQR symptom domain; Age
Gamma GLM: Generalized linear model Gamma log-link. EQ-5D was pre-transformed as EQ-5D + 0.66 in order to calculate the Gamma GLM with all scores (including
negative values). It was post-transformed as EQ-5D – 0.66
Coefficients with best fitting for equations are in bold
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validation is strongly recommended. Finally, mapping
onto the crosswalk version EQ-5D-5 L tariff means there
is a “double-mapping”, however there is no other Spanish
EQ-5D-5 L tariff available for use.
Despite these limitations, the R-squared and the
goodness-of-fit measures presented values as good as or
better than the reported in previous mapping studies
[8, 20]. The results indicate that FIQR con be mapped
onto EQ-5D-5 L, 15D, AQoL-8D and SF-6D with good
precision in a FM sample .
Conclusion
Mapping algorithms developed in this study enable the
estimation of utility values from scores in a FM specific
questionnaire. FIQR con be mapped onto EQ-5D-5 L,
15D, AQoL-8D and SF-6D with good precision in this
population. Therefore, the current study enables CUA
using data from the most used FM specific disease
questionnaire.
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